US biotech company 2seventy bio sold its hemophilia A program, along with rights to some of its gene-editing tech to Denmark-based pharmaceutical company Novo Nordisk. The transaction was valued at USD 40 million approximately.
This agreement grants Novo Nordisk access to 2seventy's hemophilia A treatment, as well as transfer of its in vivo gene-editing technology, including megaTAL technology, for non-oncology and non-autoimmune disease-related projects. Two of the staff members who were working on the hemophilia A program will also move to Novo Nordisk.
2seventy plans to focus exclusively on the development and commercialization of its multiple myeloma treatment Abecma (idecabtagene vicleucel), a BCMA-targeted CAR T-cell therapy.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.